REGENXBIO Inc. (RGNX)
- Sector
- Biotechnology
- Last price
- $7.24
- As of
Kresmion compiles this page from RGNX's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
REGENXBIO Inc. (RGNX): 6 institutional managers tracked by Kresmion reported non-option positions in their 2026Q3 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-11-05.
See the full RGNX dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for RGNX on one page. Preview it with sample data, then open it live with a free account.
Preview the RGNX dossierActive events for RGNX
- high13F: funds added
5 tracked funds increased RGNX this 2026Q3, institutional consensus
- high13F: large increase
Point72 Asset Management, L.P. added +378% to RGNX (2026Q3)
- high13F: large increase
CITADEL ADVISORS LLC added +66% to RGNX (2026Q3)
- high13F: large increase
D. E. Shaw & Co., Inc. added +50% to RGNX (2026Q3)
- high13F: large increase
TWO SIGMA INVESTMENTS, LP added +184% to RGNX (2026Q3)
FREE, NO ACCOUNT
Every event on RGNX, as it fires
You are seeing 5 of 24 events recorded on RGNX since 2026-05-26.
The five above all landed on 2026-11-18. The other 19 were recorded on 8 other days. 13 of the 24 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
RGNX positions held by the managers we follow (2026Q3)
What the managers we follow bought and sold in Q3 2026
| Manager / security | Market value | % of reported value |
|---|---|---|
| TWO SIGMA INVESTMENTS, LP FundCUSIP 75901B107 · 2026Q3 | $14.3M | 0.01% |
| CITADEL ADVISORS LLC FundCUSIP 75901B107 · 2026Q3 | $8.4M | 0.00% |
| D. E. Shaw & Co., Inc. FundCUSIP 75901B107 · 2026Q3 | $8.1M | 0.01% |
| Point72 Asset Management, L.P. FundCUSIP 75901B107 · 2026Q3 | $5M | 0.01% |
| MILLENNIUM MANAGEMENT LLC FundCUSIP 75901B107 · 2026Q3 | $3.8M | 0.00% |
| RENAISSANCE TECHNOLOGIES LLC FundCUSIP 75901B107 · 2026Q3 | $888K | 0.00% |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. The share of reported value is each position's value over the sum of the values that manager reported for the quarter; option lines are not in that sum, as on each fund page. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, RGNX
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
Going concern statement
RGNX's 10-Q filed Nov 5, 2026 states:
These conditions raise substantial doubt about the Company's ability to continue as a going concern within 12 months from the date these consolidated financial statements were issued.
Read the 10-Q on SEC EDGAR Every company with a going concern statement
More data on RGNX
RGNX mentioned in Kresmion daily briefs
RGNX against its peers
RGNX's operating margin of -94.6% ranks in the 46th percentile of 13 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.
| Metric | RGNX | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 170M USD | 9.0M USD | 74 | 16 |
| Gross margin | n/a | 76.2% | n/a | 6 |
| Operating margin | -94.6% | -91.4% | 46 | 13 |
| Net margin | -113.8% | -126.3% | 54 | 13 |
| Return on equity | -188.7% | -58.4% | 3 | 19 |
| 1 year | -33.4% | -1.4% | 31 | 20 |
Peers (21): NGNE, MNPR, CBIO, OVID, DMAC, VALN, STTK, ZVRA, GYRE, MYGN, MDXG, CAPR, EPRX, CADL, SANA, ENTX, RLMD, OBIO, SRZN, ARVN, PHAT. Left out: SLBT (no annual filing), BLSM (no annual filing), IAM (no annual filing), ETRA (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (RGNX: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Cite this data
Kresmion counts the managers it follows that reported a non-option position in RGNX on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on RGNX in the last 180 days.
Upstream: SEC EDGAR filings for RGNX
Kresmion, "REGENXBIO Inc. (RGNX) institutional holdings and SEC filings", data as of 2026-11-18, https://kresmion.com/research/RGNX. Upstream data: SEC EDGAR filings for RGNX.
Link to this data (HTML):
<a href="https://kresmion.com/research/RGNX">REGENXBIO Inc. (RGNX) institutional holdings and SEC filings (Kresmion)</a>
Writing about this? Press contact and ready-to-quote figures
Follow RGNX on a live board
Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to RGNX for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.